TOVX — Theriva Biologics, Inc.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 894158 ·
Last close
$0.22
Market Cap
$10.10M
52W High
$0.86
52W Low
$0.16
ADV30
489,793
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -3,295,000 | -3,217,000 | 34,857,000 | 11,337,000 | 22,670,000 |
| Mar 2026 | 300,000 | — | -2,127,000 | -2,044,000 | 38,248,000 | 14,431,000 | 22,849,000 |
| Dec 2025 | 0 | — | -2,063,000 | -1,996,000 | 38,239,000 | 13,056,000 | 22,856,000 |
| Sep 2025 | 0 | — | -4,440,000 | -4,361,000 | 30,836,000 | 7,528,000 | 24,098,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-14,369,000
Investing CF
$-19,000
Financing CF
$18,987,000
CapEx
$-19,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.98
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-360,754,000
Inventory
—
Receivables
$1,786,000
ST Investments
—
EBIT TTM
$-21,762,000
Pretax Income TTM
$-21,459,000
Interest Exp TTM
—
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$300,000
EBITDA
$-11,963,000
Free Cash Flow
$-6,694,250
Enterprise Value
$3,579,024
Total Cash
$11,337,000
Total Debt
$3,553,000
Shares Out
45,892,668
Trailing EPS
$1.44
Book Value
$0.27
ROE
-101.9%
ROA
-21.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -24,051,000 | -23,739,000 | 38,239,000 | 22,856,000 | 15,383,000 | -16,669,000 |
| Dec 2024 | 0 | -19,427,000 | -25,653,000 | 35,352,000 | 16,285,000 | 19,067,000 | -16,937,000 |
| Dec 2023 | 0 | -21,431,000 | -18,349,000 | 55,219,000 | 15,522,000 | 39,697,000 | -18,996,000 |
| Dec 2022 | 0 | -21,581,000 | -19,685,000 | 71,861,000 | 17,297,000 | 54,564,000 | -19,082,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.20
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AZTR | Azitra, Inc. | $10.18M | $0.17 | — |
| BIOE | Bio Essence Corp | $9.79M | $0.18 | — |
| ENLV | Enlivex Ltd. | $10.46M | $0.60 | — |
| MDCX | Medicus Pharma Ltd. | $9.60M | $0.15 | — |
| APRE | Aprea Therapeutics, Inc. | $9.58M | $0.76 | — |
News headlines (Yahoo Finance, 1h cache)
Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results
2026-08-11 12:00 · Yahoo
Theriva™ Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancre
2026-08-06 12:00 · Yahoo
Theriva™ Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients wi
2026-07-07 12:00 · Yahoo
Theriva™ Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer Research
2026-06-11 12:00 · Yahoo
Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results
2026-05-05 20:30 · Yahoo
Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting
2026-04-17 20:05 · Yahoo
Theriva™ Biologics Announces Positive End-of-Phase 2 Meeting with U.S. FDA Regarding the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma
2026-03-23 12:00 · Yahoo
Theriva™ Biologics Reports Full-Year 2025 Operational Highlights and Financial Results
2026-03-12 12:00 · Yahoo
Theriva™ Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple Indications
2026-02-18 13:00 · Yahoo
Theriva™ Biologics Announces Upcoming Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at APAO 2026
2026-02-03 13:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.